InsiderTrades

Form 4 for ROIV Roivant Sciences Ltd.

Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-19 · accession 0001635088-26-000019 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-02-23 2026-02-19+ ROIV Torti Frank Pres, Vant COB M - OptEx $3.85 +3.00M 14.75M +26% +$11.55M
DM 2026-02-23 2026-02-19+ ROIV Torti Frank Pres, Vant COB S - Sale+OE $27.35 -3.00M 13.74M -18% -$82.04M
DM 2026-02-23 2026-02-19+ ROIV Torti Frank Pres, Vant COB M - OptEx $0.00 -3.00M 3.61M -45% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Shares 2026-02-23 M A 587,390 $3.85 14,323,937 D — —
2 Common Common Shares 2026-02-23 S D 587,390 $27.51 13,736,547 D — — (F4) These Common Shares were sold in multiple transactions at prices ranging from $27.14 to $27.80, inclusive. (F1) The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
3 Common Common Shares 2026-02-19 M A 1,400,000 $3.85 15,136,547 D — —
4 Common Common Shares 2026-02-19 S D 1,400,000 $27.42 13,736,547 D — — (F2) These Common Shares were sold in multiple transactions at prices ranging from $27.00 to $27.64, inclusive. (F1) The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
5 Common Common Shares 2026-02-20 M A 1,012,610 $3.85 14,749,157 D — —
6 Common Common Shares 2026-02-20 S D 1,012,610 $27.15 13,736,547 D — — (F3) These Common Shares were sold in multiple transactions at prices ranging from $26.70 to $27.45, inclusive. (F1) The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
7 Derivative Stock Option (Right to Buy) 2026-02-19 M D 1,400,000 $0.00 4,626,184 D $3.85 · — to 2032-04-19 1,400,000 Common Shares (F5) Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).
8 Derivative Stock Option (Right to Buy) 2026-02-23 M D 587,390 $0.00 3,026,184 D $3.85 · — to 2032-04-19 587,390 Common Shares (F5) Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).
9 Derivative Stock Option (Right to Buy) 2026-02-20 M D 1,012,610 $0.00 3,613,574 D $3.85 · — to 2032-04-19 1,012,610 Common Shares (F5) Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).